Stralem & Co. Inc. trimmed its position in Eli Lilly and Co (NYSE:LLY) by 19.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,600 shares of the company’s stock after selling 2,600 shares during the period. Stralem & Co. Inc.’s holdings in Eli Lilly and were worth $895,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of LLY. Acrospire Investment Management LLC lifted its stake in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and during the second quarter worth $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and during the second quarter worth $129,000. Willingdon Wealth Management acquired a new stake in shares of Eli Lilly and during the third quarter worth $138,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of Eli Lilly and during the third quarter worth $142,000. Institutional investors and hedge funds own 76.35% of the company’s stock.

In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction on Monday, December 11th. The shares were sold at an average price of $86.46, for a total value of $1,080,750.00. Following the completion of the transaction, the senior vice president now owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 in the last ninety days. 0.20% of the stock is owned by corporate insiders.

Eli Lilly and Co (NYSE:LLY) traded down $1.69 during midday trading on Wednesday, reaching $85.29. 4,878,300 shares of the company were exchanged, compared to its average volume of 2,955,040. The firm has a market capitalization of $94,770.00, a P/E ratio of 40.61, a PEG ratio of 1.63 and a beta of 0.35. Eli Lilly and Co has a 52 week low of $74.00 and a 52 week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 earnings per share. equities analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.64%. Eli Lilly and’s payout ratio is currently 99.05%.

Several equities research analysts have recently commented on LLY shares. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price objective for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 12th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $85.52 to $115.00 in a research note on Friday, January 5th. Berenberg Bank reiterated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Finally, Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus price target of $92.75.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/01/17/eli-lilly-and-co-lly-holdings-trimmed-by-stralem-co-inc.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.